Calpains is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Calpains are a family of calcium-dependent cysteine proteases that perform limited proteolysis of substrate proteins in response to intracellular calcium signals. In the brain, calpains play essential roles in synaptic plasticity, cytoskeletal remodeling, and signal transduction. However, pathological calpain overactivation driven by calcium dysregulation is a central mechanism linking amyloid-beta toxicity, tau] hyperphosphorylation, synaptic destruction, and neuronal death in Alzheimer's disease and other neurodegenerative conditions (Bhatt et al., 2012).
Calpain overactivation in AD operates through a devastating cascade: Aβ-induced calcium influx activates calpains, which cleave calpastatin (their endogenous inhibitor), generating a self-amplifying loop of unrestrained proteolysis. Activated calpains then cleave p35 to p25 (constitutively activating CDK5, degrade PP2A (the major tau] phosphatase), truncate tau] into aggregation-prone fragments, and proteolyze synaptic and cytoskeletal proteins — together driving the major pathological hallmarks of AD.
The human genome encodes 15 calpain isoforms. The two ubiquitous "classical" calpains are most relevant to neurodegeneration:
| Isoform |
Also Known As |
Ca2+ Requirement |
Brain Expression |
Disease Relevance |
| Calpain-1 |
μ-calpain |
Micromolar (~3-50 μM) |
[Neuron]s] (synapses, cell body) |
Synaptic plasticity; protective at physiological levels |
| Calpain-2 |
m-calpain |
Millimolar (~0.4-0.8 mM) in vitro; lower in vivo due to regulation |
neurons, glia |
Pathological; mediates excitotoxic damage |
| Calpain-5 |
— |
Unknown |
Retina, brain |
Retinal degeneration |
| Calpain-10 |
— |
Unknown |
Ubiquitous |
Linked to type 2 diabetes susceptibility |
Classical calpains (calpain-1 and -2) are heterodimers:
Large (catalytic) subunit (~80 kDa; CAPN1 or CAPN2):
- Domain I: N-terminal anchor helix
- Domain II (protease core): Cysteine protease catalytic domain (papain-like fold); divided into IIa and IIb subdomains containing the catalytic triad (Cys105, His262, Asn286)
- Domain III: C2-like domain; binds phospholipids and calcium
- Domain IV: Penta-EF-hand domain; binds calcium; mediates heterodimerization
Small (regulatory) subunit (~28 kDa; CAPNS1):
- Domain V: Glycine-rich hydrophobic region
- Domain VI: Penta-EF-hand domain; dimerizes with domain IV
- Calcium binds to EF-hand domains in both subunits
- Conformational change brings IIa and IIb subdomains together, assembling the active site
- Autolysis of the N-terminal anchor removes the small subunit
- Active calpain performs limited proteolysis of substrates (cuts at specific sites, not complete degradation)
Calpastatin (encoded by CAST) is the only known endogenous specific inhibitor of classical calpains:
- Contains four inhibitory domains, each capable of inhibiting one calpain molecule
- Binds to calcium-activated calpain with extremely high affinity
- Calpastatin itself is a calpain substrate — creating a destructive feedback loop when calpain is overactivated
- Critical AD finding: Calpastatin is markedly depleted (~50-75%) in AD brain (Bhatt et al., 2008), removing the brake on calpain activity
- Calpastatin overexpression in tau] P301L mice prevents tauopathy, tau] fragmentation, and neurodegeneration, and restores normal lifespan (Bhatt et al., 2014)
In AD, multiple sources of pathological calcium elevation drive calpain overactivation:
- Aβ oligomer-formed membrane pores: Direct calcium influx into neurons
- NMDA receptor] receptor] overactivation: Excitotoxic calcium entry
- Ryanodine receptor leak: Chronic ER calcium release (especially with presenilin mutations)
- Mitochondrial calcium buffering failure: Impaired sequestration of excess calcium
- Reduced calpastatin: Loss of endogenous inhibition amplifies the cascade
One of the most pathologically significant calpain substrates is p35, the regulatory activator of CDK5:
- Calpain cleaves p35 (306 aa) to generate p25 (208 aa) — removing the membrane-targeting myristoylation signal
- p25 constitutively activates CDK5 and causes its mislocalization from the membrane to the cytoplasm and nucleus
- CDK5/p25 hyperphosphorylates tau] at multiple AD-relevant sites (Ser202, Thr205, Ser235, Ser404)
- CDK5/p25 also phosphorylates APP, enhancing BACE1, reducing its activity
- Calpain also cleaves I2PP2A/SET, generating fragments that inhibit remaining PP2A
- Net effect: ~50% reduction in PP2A activity in AD brain
- Combined with CDK5/p25 activation, this creates a kinase-phosphatase imbalance maximally favoring tau hyperphosphorylation]
Calpains directly cleave tau](/proteins/tau at multiple sites:
- Generate truncated tau fragments (e.g., tau 17 kDa fragment) that are highly aggregation-prone
- Truncated tau acts as a seed for further tau oligomerization and tangle formation
- Calpain-generated tau fragments are found in NFTs in AD brain
- These fragments are more neurotoxic than full-length hyperphosphorylated tau
- Calpain activation increases BACE1 expression and stability in neurons
- Mechanism involves calpain-mediated cleavage of the BACE1 translational repressor GGA3
- Increased BACE1 enhances Aβ production, further driving calcium influx — a feed-forward loop
Calpain-mediated proteolysis of synaptic proteins drives cognitive decline:
| Substrate |
Function |
Consequence of Cleavage |
| αII-spectrin (fodrin) |
Membrane cytoskeleton scaffold |
Loss of [dendritic spine] structure; spectrin breakdown products (SBDPs) are biomarkers |
| PSD-95 |
Postsynaptic scaffold |
Disrupted receptor clustering and synaptic transmission |
| Homer1 |
Postsynaptic scaffold |
Impaired metabotropic glutamate receptor signaling |
| NMDA receptor] receptor subunits |
Excitatory receptor |
Altered receptor function and trafficking |
| Dynamin-1 |
Synaptic vesicle endocytosis |
Impaired synaptic vesicle recycling |
| GAP-43 |
Growth cone/synaptic plasticity |
Reduced synaptic remodeling |
¶ Apoptosis and Necrosis
Calpain activation contributes to neuronal death through multiple mechanisms:
- Cleavage of pro-caspase-3 → activation of caspase cascade → apoptosis
- Cleavage of Bid → truncated Bid (tBid) → mitochondrial cytochrome c release
- Degradation of Bcl-2 and Bcl-xL → loss of anti-apoptotic protection
- Cleavage of AIF (apoptosis-inducing factor) → caspase-independent cell death
- Calpain-caspase crosstalk: caspases also cleave calpastatin, further amplifying calpain activity
- α-Synuclein is a calpain substrate; truncated fragments promote aggregation
- Calpain-mediated cleavage of Parkin reduces its E3 ligase activity
- Dopaminergic neurons in the substantia nigra are particularly vulnerable to calcium-calpain damage
- TDP-43 is cleaved by calpains to generate aggregation-prone 25 kDa and 35 kDa fragments found in ALS inclusions
- Motor neurons express high calpain-1 levels, increasing vulnerability
- Mutant huntingtin is cleaved by calpains, generating toxic N-terminal fragments
- Calpain-resistant huntingtin mutants show reduced toxicity in models
- Acute calpain activation is a hallmark of TBI
- αII-spectrin breakdown products (SBDPs) in CSF and blood are established TBI biomarkers
- Chronic calpain activation after TBI may contribute to post-traumatic neurodegeneration (CTE)
| Compound |
Mechanism |
Status |
Key Findings |
| SNJ-1945 (BLD-2660) |
Reversible, brain-penetrant calpain inhibitor |
Phase 1 |
Reduces tau pathology] in AD mice; good oral bioavailability |
| PD150606 |
Non-competitive calpain-1/2 inhibitor |
Preclinical |
Selectively inhibits calpains vs. cathepsins |
| MDL-28170 |
Cell-permeable calpain inhibitor |
Preclinical |
Neuroprotective in excitotoxicity and ischemia models |
| E-64d |
Broad cysteine protease inhibitor |
Preclinical |
Reduces Aβ pathology; limited selectivity |
- Calpastatin gene therapy: AAV-mediated CAST overexpression prevents tauopathy in mice and restores lifespan
- Calpastatin-mimetic peptides: Smaller peptides based on the inhibitory domain of calpastatin
- Calpastatin stabilization: Preventing calpain-mediated degradation of calpastatin
Rather than directly inhibiting calpains, targeting upstream calcium dysregulation:
- Calpain-generated αII-spectrin fragments (SBDP150, SBDP145) are detectable in CSF and blood
- Established biomarkers in TBI; under investigation for AD
- Distinguish calpain-mediated (SBDP145) from caspase-mediated (SBDP120) cleavage patterns
The study of Calpains has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- [Bhatt AB, et al. Mechanistic involvement of the calpain-calpastatin system in Alzheimer neuropathology. Int J Clin Exp Pathol. 2012;5(7):606-622. DOI
- [Bhatt AB, et al. Marked calpastatin (CAST] depletion in Alzheimer's Disease accelerates cytoskeleton disruption and neurodegeneration: neuroprotection by CAST overexpression. J Neurosci. 2008;28(47):12241-12254. DOI
- [Bhatt AB, et al. Specific calpain inhibition by calpastatin prevents tauopathy and neurodegeneration and restores normal lifespan in tau P301L mice. J Neurosci. 2014;34(28):9222-9234. DOI
- [Lee MS, et al. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature. 2000;405(6784):360-364. DOI
- [Goll DE, et al. The calpain system. Physiol Rev. 2003;83(3):731-801. DOI
- [Bhatt AB, et al. Synaptotoxicity of Alzheimer beta amyloid can be explained by its membrane perforating property. PLoS One. 2009;4(1):e4201. DOI
- [Bhatt AB, et al. Calpain inhibitors as potential therapeutic modulators in neurodegenerative diseases and traumatic brain injury. J Med Chem. 2022;65(2):743-766. DOI
- [Patrick GN, et al. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature. 1999;402(6762):615-622. DOI
- [Bhatt AB, Bhatt Y. Regulation of PP2A by calpain and implications for Alzheimer's Disease. Front Aging Neurosci. 2015;7:209. DOI
- [Wang KKW. Calpain and caspase: can you tell the difference? Trends Neurosci. 2000;23(1):20-26. DOI: 10.1016/S0166-2236(99)
- [Bhatt AB. Calpain-mediated proteolysis of the spectrin cytoskeleton in a mouse model of Alzheimer's Disease. J Neurosci Res. 2013;91(7):884-893. DOI